Re-appointed Mr. Atul Kumar Sethi (DIN: 00245685), who holds office up to 30th November 2025 as a Managing Director of the company for further period of three (3) consecutive years commencing ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.3 pts more than Nifty Microcap 250 and 8.2 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of Shree Pacetronix Ltd, meeting on August 7, 2025, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with the auditor issuing an unmodified limited review opinion. The board also approved a preferential issue to promoter Mr. Akash Sethi (son of MD Mr. Atul Kumar Sethi), involving 75,150 equity shares at Rs. 81 each and up to 2,25,450 convertible warrants at the same price, aggregating up to Rs. 2.43 crore. Post-issue, Akash Sethi's holding will rise from 0.35% to 8.03% of equity capital, triggering a mandatory open offer under SEBI takeover rules. Additionally, the board re-appointed Mr. Atul Kumar Sethi as Managing Director for three years from December 1, 2025 to November 30, 2028, subject to shareholder approval. The 37th Annual General Meeting has been scheduled for September 3, 2025, via video conferencing.
Existing shareholders may see dilution of around 7.7% if all warrants are converted, and a mandatory open offer will follow. The promoter family's increased stake signals continued insider confidence, while the small fund raise (Rs. 2.43 crore) is a modest capital infusion rather than a transformative event. MD continuity provides leadership stability through November 2028.